ViiV Healthcare has announced steps to widen access to a sought-after HIV medicine in low- and middle-income countries, ...

ViiV Healthcare, the HIV-focused joint venture majority owned by GSK , said on Monday it has expanded its licensing deal with ...

Cabenuva is administered every two months and was offered to patients who achieved viral suppression from daily treatments.

Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

Centre for Epidemiological Modelling and Analysis (CEMA), have released results of three studies that could significantly ...

Experts have proposed new treatment modes for older people with HIV. The new treatment does not cause the health-threatening ...

The agreement allows manufacturers to develop, manufacture and supply generic long-acting injectable cabotegravir for treatment in 133 countries.

A breakthrough HIV drug that only needs to be injected twice a year to offer near-total protection from the virus and ...

New Delhi: Aurobindo Pharma on Tuesday said it will manufacture and supply the long-acting injectable HIV treatment ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

ViiV & MPP extend voluntary licensing long-acting injectable HIV treatment, Indian pharma to benefit: Our Bureau, Bengaluru Tuesday, July 15, 2025, 12:45 Hrs [IST] ViiV Healthcare ...

Merck MRK announced that the FDA has accepted for review the new drug application (“NDA”) seeking approval for its ...